Alex Howarth

Chief Financial Officer at Madrigal Pharmaceuticals - Conshohocken, PA, US

Alex Howarth's Colleagues at Madrigal Pharmaceuticals
Pete Vu

Medical Science Liaison

Contact Pete Vu

John Franc

Vice President, External Scientific Affairs & Global Project Lead

Contact John Franc

Jeffrey Edwards

Vice President of Clinical Science

Contact Jeffrey Edwards

Sean PharmD.

Vice President Global Market Access & Trade

Contact Sean PharmD.

Brian Lynch

Senior Vice President and General Counsel

Contact Brian Lynch

Tom Hare

Senior Vice President, Clinical Management

Contact Tom Hare

View All Alex Howarth's Colleagues
Alex Howarth's Contact Details
HQ
484-380-9263
Location
Greater Philadelphia
Company
Madrigal Pharmaceuticals
Alex Howarth's Company Details
Madrigal Pharmaceuticals logo, Madrigal Pharmaceuticals contact details

Madrigal Pharmaceuticals

Conshohocken, PA, US • 50 - 99 Employees
Major Drugs

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy.Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial.A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.For more information about Madrigal, please visit out website at https://www.madrigalpharma.com/ and follow us on Twitter at @MadrigalPharma.

Biotechnology Cleantech Healthcare Pharmaceuticals Wind Power Major Drugs Pharmaceutical Preparations
Details about Madrigal Pharmaceuticals
Frequently Asked Questions about Alex Howarth
Alex Howarth currently works for Madrigal Pharmaceuticals.
Alex Howarth's role at Madrigal Pharmaceuticals is Chief Financial Officer.
Alex Howarth's email address is ***@madrigalpharma.com. To view Alex Howarth's full email address, please signup to ConnectPlex.
Alex Howarth works in the Major Drugs industry.
Alex Howarth's colleagues at Madrigal Pharmaceuticals are Pete Vu, Gareth Brisbane, John Franc, Jeffrey Edwards, Sean PharmD., Brian Lynch, Tom Hare and others.
Alex Howarth's phone number is 484-380-9263
See more information about Alex Howarth